

FORM 7

December 2022 - MONTHLY PROGRESS REPORT

Name of Listed Issuer: **ChitogenX Inc. (the “Company” or the “Issuer”)**

Trading Symbol: **CHGX**

Number of Outstanding Listed Securities: **51 038 776**

Date: **January 6th, 2023**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company is focused on the following 5 strategies to create value for its investors:

- 1. Leverage the new corporate name, ChitogenX Inc., to better reflect the Company's expanded clinical and commercial opportunities, mission, values, and core competencies.**
- 2. Complete its Rotator Cuff Tear Repair U.S. Phase I/II clinical trial program to establish and validate the regenerative medicine platform.**

3. Accelerate the development of other orthopedics application for ORTHO-R by leveraging the Polytechnique partnership to obtain non-dilutive grants.
 4. Leverage the Company's proprietary platform beyond orthopedic applications by seeking R&D and/or development partners for each high potential application.
 5. Advance manufacturing and regulatory initiatives to commercialize its medical grade Chitosan globally.
2. Provide a general overview and discussion of the activities of management.

During the period:

- Patient enrollment in the U.S. Phase I/II rotator cuff repair clinical trial continued to progress. After successfully completing the initial portion of its U.S. Phase I/II ORTHO-R rotator cuff tear repair clinical trial requiring staggered enrolment of 5 patients, the sites are now recruiting for the trial on a parallel basis. We expect the recruiting of patients to accelerate as a result.
 - 8 of 9 sites are now actively recruiting patients to complete the clinical trial patients' enrollment. We expect the 9th site to be activated in Q1-23 calendar.
 - Advanced discussions with worldwide key opinion leaders to use the Company's technology for non-orthopaedics applications. 5 areas of high unmet medical needs were identified, and the Company's is proceeding to develop protocols for their development.
 - Initiated manufacturing and regulatory initiatives to manufacture and market the Company's medical grade chitosan in the \$US250M medical grade global chitosan market following the development completion of a low cost optimized GMP manufacturing process for the chitosan portion of the ORTHO-R product with an industry leading 3-year shelf life.
 - The surgical and residency proof of concept portions of the pre-clinical meniscus repair program based on the previously announced \$750K grant obtained by the Company was successfully completed in a large animal model. This is the second orthopedic tissue, rotator cuff tendon being the other, where our ORTHO R product was proven to stick to the target tissue to deliver the benefits of PRP. Full Results are expected mid-2023 calendar. This will be the second proof of concept orthopedic model for ChitogenX, thus validating its platform for soft tissue repair.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Nothing applicable during the period

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Nothing applicable during the period.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Nothing applicable during the period

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Nothing applicable during the period.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Nothing applicable during the period.

8. Describe the acquisition of new customers or loss of customers.

Nothing applicable during the period.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks

Nothing applicable during the period.

10. Report on any employee hiring's, terminations, or lay-offs with details of anticipated length of lay-offs.

Nothing applicable during the period.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Nothing applicable during the period.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Nothing applicable during the period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Company reached an agreement with holders of existing convertible and non-convertible debentures for the accelerated conversion of \$2.6 million worth of convertible debentures as well as the extension of the \$3.0 million non-convertible debenture maturity from November 2023 to February 2025.

The Company also secured \$1.2 million to fund operations and support initiatives related to the Phase I/II Clinical trial for rotator cuff tear repair

14. Provide details of any securities issued and options or warrants granted.

Nothing applicable during the period

15. Provide details of any loans to or by Related Persons.

Nothing applicable during the period.

16 Provide details of any changes in directors, officers or committee members.

Nothing applicable during the period.

17 Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Nothing applicable during the period.

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All the information in this Form 7 Monthly Progress Report is true.

Dated: January 6th, 2022

ChitogenX Inc.
/s/ Luc Mainville
Senior VP & Chief Financial Officer
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer ChitogenX Inc.	December 2022	YY/MM/D 2023/01/06
Issuer Address 16667, Boul. Hymus,		
City/Province/Postal Code Kirkland, Quebec, H9H 4R9	Issuer Fax No. 514.694.0443	Issuer Telephone No. 514.694.0865
Contact Name Luc Mainville	Contact Position Sr. VP & CFO	Contact Telephone No. (514) 693-8854
Contact Email Address mainville@chitogenx.com	Web Site Address www.chitogenx.com	